Last reviewed · How we verify
Nebulized arformoterol
At a glance
| Generic name | Nebulized arformoterol |
|---|---|
| Also known as | Brovana |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (PHASE3)
- A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients (PHASE4)
- Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD (PHASE4)
- A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD (PHASE3)
- Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers (NA)
- Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |